Dominick DiPaolo, CQA CQE

Sr. Vice President Of Quality at Elevar Therapeutics

Dominick DiPaolo, CQA CQE, has a diverse and extensive work experience in the pharmaceutical industry. Starting in 2002, they worked at Novartis Pharmaceuticals as a Senior Quality Assurance Specialist. Dominick then joined Pfizer Inc. in 2003 as a Manager of Corporate Quality Assurance. In 2005, they became the Director of Global Quality at Barr Laboratories. From 2007 to 2011, they held Vice President roles in quality, compliance, and regulatory affairs at Morton Grove Pharmaceutical, Inc. and G&W Laboratories. In 2011, they joined Tris Pharma as the Sr. Vice President of Quality, Compliance & Regulatory Affairs. From 2015 to 2018, they served as the Senior Vice Present of Quality & Regulatory Affairs at Matinas BioPharma. In 2019, they became the Executive Vice President of Quality at RK Pharma Inc. Most recently, since June 2021, they have held the position of Sr. Vice President of Quality at Elevar Therapeutics. Dominick DiPaolo has demonstrated expertise in quality assurance, compliance, and regulatory affairs throughout their career.

Dominick DiPaolo, CQA CQE, obtained a Master of Science (M.S.) degree in Microbiology from Seton Hall University. Dominick pursued their master's degree from 2002 to 2004. Prior to that, they completed their Bachelor of Science (B.S.) degree in Biotechnology/Microbiology from Rutgers University. Dominick'sundergraduate studies were carried out between 1994 and 1999.

Location

Wilmington, United States

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Elevar Therapeutics

Elevar Therapeutics is a pharmaceutical company that specializes in the development of therapies for unmet medical needs in cancer. The company is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with thepotential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent.Elevar Therapeutics holds worldwide rights for rivoceranib excluding China and has partnered for development and marketing in South Korea.


Industries

Employees

11-50

Links